Universal Health Services, Inc.

Universal Health Services, Inc. (UHS) Market Cap

Universal Health Services, Inc. has a market capitalization of $9.09B.

Price: $145.17

2.45 (1.72%)

Market Cap: 9.09B

NYSE · time unavailable

CEO: Marc D. Miller

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1981-07-09

Website: https://uhs.com

Universal Health Services, Inc. (UHS) - Company Information

Market Cap: 9.09B|Sector: Healthcare

Company Profile

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 24, 2022, it owned and/or operated 363 inpatient facilities, and 40 outpatient and other facilities located in 39 states; Washington, D.C.; the United Kingdom; and Puerto Rico. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.

Analyst Sentiment

73%
Strong Buy

From 20 Active Polls

1Y Forecast: $216.00

▲ +48.8% Potential Upside

Consensus Target Metrics

Low Bound

$165

Median

$204

High Bound

$310

Average

$216

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$216.00
▲ +48.79% Upside
Low Target
$165.00
14% Risk
Median Target
$204.00
41% Mid
High Target
$310.00
114% Max
Consensus
Hold
18 / 43 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)9,08910,92913,86213,15711,65812,20811,76915,23812,185
Enterprise Value ($M)14,09515,93619,23118,15516,52817,17516,59920,23817,052
Price to Earnings Ratio (P/E)5.837.847.778.828.259.648.8514.7210.54
Price/Earnings-to-Growth Ratio (PEG)38.481.791.842.3310.386.32
Price to Sales Ratio (P/S)0.512.433.092.932.722.982.863.843.12
Price to Book Ratio (P/B)1.181.451.911.821.661.801.772.311.88
Price to Free Cash Flow Ratio (P/FCF)10.1759.2447.2398.8441.20100.8728.53179.1727.83
Enterprise Value to Sales (EV/Sales)3.554.294.043.864.194.035.114.36
Enterprise Value to EBITDA (EV/EBITDA)5.0524.2124.4726.3425.0528.2526.6037.8429.53
Debt to Equity Ratio1.790.680.760.710.710.750.740.770.77

UHS Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$145.17
Intrinsic Value$220.63
Market Alignment
Undervalued by 52.0%relative to calculated intrinsic value
9.00%
Exp: 8%8%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$1.62B
Perpetuity TV Value$30.40B
Discounted TV (PV)$12.84B
TV Weighting %62.2%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 UNIVERSAL HEALTH SERVICES INC CLAS (UHS) — Investment Overview

🧩 Business Model Overview

Universal Health Services operates a network of inpatient facilities and related services in the U.S., with a meaningful emphasis on behavioral health (including acute psychiatric and specialty/substance-use services) alongside acute-care hospital operations. The value chain is built around (1) acquiring and operating licensed healthcare facilities, (2) staffing and operating them to deliver clinically appropriate care, (3) managing patient flow through physician relationships and referral channels, and (4) billing payers under government programs and commercial insurance arrangements. Patient volumes and length-of-stay drive utilization, while payer mix and reimbursement terms drive net revenue realization.

A key source of customer stickiness comes from the combination of licensed capacity, established referral patterns, and discharge planning pathways. While patients can choose providers, referral sources and payer/provider administrative infrastructure reduce churn, and rebuilding comparable local capacity is slow due to staffing, licensing, and operational ramp requirements.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated from facility-based clinical care, typically recognized through a mix of reimbursement structures that include per diem and other case/service-based models, with payers spanning government programs (Medicare and Medicaid) and commercial insurers. Monetisation is driven by:

  • Inpatient services: Core volume engine; profitability depends on occupancy, acuity, coding/documentation, and clinical outcomes that support appropriate reimbursement.
  • Behavioral health and specialty services: Revenue tends to be sensitive to demand trends for mental health and substance-use treatment, as well as regulatory and payer coverage policies.
  • Outpatient and ancillary services (where present): Provides diversification and can support smoother utilization across the care continuum.

Margin drivers generally include labor efficiency (nursing and clinical staffing models), pharmacy and supply utilization, denial management, and the ability to keep growth aligned with operating capacity. Because healthcare is heavily compliance- and documentation-dependent, net revenue realization is strongly influenced by coding accuracy, documentation integrity, and payer contracting terms.

🧠 Competitive Advantages & Market Positioning

UHS’s moat is anchored less in branding and more in hard-to-replicate operating and regulatory capabilities that support licensed capacity and reliable reimbursement. The competitive advantages are best characterized as regulatory/operational barriers to entry plus integrated referral and care delivery ecosystems.

  • High barriers to entry (regulatory + accreditation + licensing): Building and scaling comparable hospital capacity requires state/federal licensing, regulatory compliance, accreditation, and substantial clinical workforce availability. This raises competitor entry costs and slows replacement of capacity in a given geography.
  • Operational expertise and reimbursement execution: Complex payers and documentation requirements create a performance gap between operators; robust denial management, coding discipline, and payer contract execution can materially affect net revenue.
  • Integrated ecosystems (referral pathways and discharge planning): Behavioral health models rely on referral sources (e.g., clinicians, managed care networks, community partners) and effective transitions of care. This dynamic supports patient flow durability and reduces effective churn versus a purely transactional model.

Competitive benchmarking: UHS’s closest public peers include Acadia Healthcare (behavioral health focus), Tenet Healthcare (acute-care hospital operator with different facility mix), and HCA Healthcare (large acute-care network with scale and contracting sophistication). Compared with these rivals, UHS’s positioning emphasizes behavioral/specialty capacity and the operational cadence of specialty care delivery, whereas larger acute-care peers typically benefit more from scale across broad hospital services. Competitors can replicate facilities over time, but the combination of licensing, staffing, and reimbursement execution remains a sustained execution advantage.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular demand and capacity rebalancing rather than purely cyclical healthcare spending:

  • Rising demand for mental health and substance-use treatment: Policy focus and improved clinical recognition support steady addressability for behavioral health providers, including inpatient and specialty levels of care.
  • Capacity constraints and replacement cycles: Healthcare facilities often face long lead times for new capacity due to licensing, workforce, and capital requirements, creating pricing and utilization support for well-run operators.
  • Site and service expansion within existing platforms: Operators can add capacity, refine service lines, and improve throughput using existing compliance and operational infrastructure.
  • Care continuum integration: Stronger linkage between inpatient stabilization, outpatient follow-up, and community-based transitions can support better clinical outcomes and improve payer confidence, supporting volume durability.

TAM expansion is primarily driven by treatment coverage, care delivery models, and the healthcare system’s need to absorb behavioral health demand into licensed care settings.

⚠ Risk Factors to Monitor

  • Reimbursement and payer policy risk: Changes in Medicare/Medicaid reimbursement methodology, commercial payer contracting, and behavioral health coverage rules can affect net revenue realization.
  • Labor availability and wage inflation: Healthcare operations are structurally sensitive to staffing supply, wage pressure, and agency utilization. Sustained labor cost increases can compress margins.
  • Regulatory, compliance, and oversight: Behavioral health and inpatient care models face heightened scrutiny related to patient safety, quality measures, and documentation. Adverse findings can increase cost and constrain growth.
  • Capital intensity and facility performance: Expansion requires meaningful capital deployment and operating ramp management; underperforming facilities can dilute consolidated returns.
  • Denials, coding, and reimbursement execution: Errors in documentation or contracting disputes can reduce cash receipts and raise earnings volatility.

📊 Valuation & Market View

Healthcare operators like UHS are typically valued through earnings power rather than asset-only metrics. Market focus often centers on:

  • EV/EBITDA and operating margin trajectory: Investors underwrite sustained profitability from utilization, net revenue realization, and cost discipline.
  • Earnings quality and cash conversion: Resolution of denials, working capital dynamics, and payer settlement patterns can influence perceived durability of earnings.
  • Facility-level performance indicators: Trends in occupancy/utilization, labor intensity, and documentation/coding performance can move sentiment.

Key valuation sensitivities typically include labor cost outlook, reimbursement environment, and visibility into facility-level throughput improvements.

🔍 Investment Takeaway

UHS’s long-term investment case rests on durable barriers to entry in licensed healthcare capacity, reinforced by execution capabilities in clinical operations and reimbursement discipline. The company’s emphasis on behavioral health and specialty care provides a defensible platform with structural demand support and an ecosystem advantage tied to referral pathways and continuity of care—advantages that are difficult to replicate quickly for new entrants or under-optimized operators.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for UHS.

newsfilecorp.com2026-05-28

UNIVERSAL HEALTH SERVICES, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Universal Health Services, Inc.'s Directors and Officers for Breach of Fiduciary Duties - UHS

New York, New York--(Newsfile Corp. - May 28, 2026) - Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Universal Health Services, Inc. (NYSE: UHS) failed to manage Universal Health in an acceptable manner, breaching their fiduciary duties to Universal Health, and whether Universal Health and its shareholders have suffered damages as a result. Attorney Joseph A.

prnewswire.com2026-05-27

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT GOLDMAN SACHS ANNUAL GLOBAL HEALTHCARE CONFERENCE

KING OF PRUSSIA, Pa., May 27, 2026 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) is scheduled to present at the Goldman Sachs Annual Global Healthcare Conference on June 9, 2026, at 8:00am ET.

prnewswire.com2026-05-27

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DIVIDEND

KING OF PRUSSIA, Pa., May 27, 2026 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that its Board of Directors voted to pay a cash dividend of $0.20 per share on June 18, 2026 to shareholders of record as of June 8, 2026.

zacks.com2026-05-27

Why Is Universal Health Services (UHS) Down 3.6% Since Last Earnings Report?

Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock?

seekingalpha.com2026-05-20

Universal Health Services, Inc. (UHS) Shareholder/Analyst Call Prepared Remarks Transcript

Universal Health Services, Inc. (UHS) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com2026-05-12

Universal Health Services, Inc. (UHS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Universal Health Services, Inc. (UHS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

zacks.com2026-05-08

Here's Why Universal Health Services (UHS) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

seekingalpha.com2026-05-04

First Eagle U.S. Fund Q1 2026 Portfolio Review

U.S. Fund A Shares (without sales charge*) posted a return of 1.17% in first quarter 2026. Leading contributors in the First Eagle U.S. Fund this quarter included gold bullion, Exxon Mobil Corporation, Noble Corporation PLC Class A, IPG Photonics Corporation and SLB Limited. The leading detractors in the quarter were Workday, Inc. Class A, Oracle Corporation, Salesforce.com, Inc., Meta Platforms, Inc. Class A and Universal Health Services, Inc, Class B.

prnewswire.com2026-04-30

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT BOFA SECURITIES HEALTH CARE CONFERENCE

KING OF PRUSSIA, Pa., April 30, 2026 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) is scheduled to present at the BofA Securities Health Care Conference on May 12, 2026, at 1:40pm PT.

zacks.com2026-04-29

Why Universal Health Services (UHS) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com2026-04-28

UHS' Q1 Earnings Beat on Strong Behavioral Health Care Admissions

Universal Health tops Q1 estimates as behavioral health admissions and patient days rise, driving revenue growth despite higher operating costs.

seekingalpha.com2026-04-28

Universal Health Services, Inc. (UHS) Q1 2026 Earnings Call Transcript

Universal Health Services, Inc. (UHS) Q1 2026 Earnings Call Transcript

zacks.com2026-04-27

Universal Health Services (UHS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Universal Health Services (UHS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com2026-04-27

Universal Health Services (UHS) Q1 Earnings and Revenues Surpass Estimates

Universal Health Services (UHS) came out with quarterly earnings of $5.62 per share, beating the Zacks Consensus Estimate of $5.29 per share. This compares to earnings of $4.84 per share a year ago.

prnewswire.com2026-04-27

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026

Consolidated Results of Operations, As Reported and As Adjusted  – Three-month periods ended March 31, 2026 and 2025: KING OF PRUSSIA, Pa., April 27, 2026 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $348.7 million, or $5.65 per diluted share, during the first quarter of 2026, as compared to $316.7 million, or $4.80 per diluted share, during the first quarter of 2025.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"UHS reported Q1’26 revenue of $4.50B and net income of $349M (EPS $5.71). YoY, revenue rose ~9.6% ($4.50B vs. $4.10B) and net income increased ~10.1% ($349M vs. $317M). QoQ, revenue was roughly flat (+0.20%) vs. Q4’25 ($4.50B vs. $4.49B), while net income declined ~21.8% ($349M vs. $446M), indicating some profit pressure quarter-to-quarter. Profitability was slightly lower QoQ: net margin fell to ~7.8% from ~9.9% in Q4’25, while operating margin was steady-to-down (~11.2% vs. ~11.5%). Gross margin remains high (~90%+), suggesting the issue is more in opex/other items rather than core pricing. Cash flow quality is solid: operating cash flow was $402M and free cash flow was $184M in Q1’26; free cash flow covered capital expenditures (~0.85x capex coverage using FCFE-style) while still remaining positive. Balance sheet resilience is supported by stable equity (~$7.53B) despite leverage (debt ~ $5.13B; net debt ~ $5.01B). Shareholder returns: the provided market data shows only +5.0% 1Y price change (no >20% momentum boost). Dividend yield is very low in the ratios (~0.0% in this dataset), but the company continues repurchases (Q1’26 buybacks $164M)."

Revenue Growth

Positive

Q1’26 revenue of $4.50B was +9.6% YoY, but only +0.2% QoQ, signaling growth that has slowed sequentially.

Profitability

Fair

Net income grew +10.1% YoY, but fell -21.8% QoQ. Net margin contracted to ~7.8% from ~9.9% (Q4’25), implying sequential cost/other pressure.

Cash Flow Quality

Positive

Operating cash flow was $402M and free cash flow $184M in Q1’26. Continued positive FCF alongside ongoing buybacks supports cash generation quality.

Leverage & Balance Sheet

Neutral

Total assets were $15.7B; equity was stable at ~$7.53B. Leverage remains moderate-to-high (net debt ~$5.01B), but interest coverage was strong (~13.5x).

Shareholder Returns

Neutral

1Y price change is +5.0% (no strong momentum). Dividend yield is minimal in the dataset, but buybacks are material (repurchased ~$164M in Q1’26), supporting total return.

Analyst Sentiment & Valuation

Positive

Consensus target ($246.57) is meaningfully above the provided price ($182.41), implying upside versus Street expectations, despite limited recent price momentum.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

UHS delivered strong top-line and earnings acceleration in Q1 2026 (revenue +9.6%, adjusted EBITDA +8.4%, adjusted EPS +16.1%) despite seasonal volume pressure. Management attributed the quarter’s acute softness to flu/respiratory and winter weather (acute volume impact ~200 bps; behavioral ~40–50 bps), while pricing improved via mix shift toward higher acuity and stronger service-line performance (cardiology/orthopedics/neurology). Underlying core growth was held back by Q1’s tough DPP and nonrecurring comparisons; the company reiterated that earnings ramp later in 2026 should get it to the ~5% core growth embedded in guidance. The biggest risk signal remains HIX dynamics: Q1 showed ~5% decline, but management increased reserves for expected premium nonpayment, projecting a low-double-digit effective decline and reiterating a full-year ~$75m pretax headwind that grows as the year progresses. Strategic upside is anchored by the March 9 Talkspace deal (single-digit effective EBITDA multiple expected by year three) and ongoing AI-driven revenue cycle improvements.

AI IconGrowth Catalysts

  • Behavioral health outpatient acceleration tied to Talkspace acquisition (announced March 9) and planned virtual intensive outpatient (IOP) step-down pathway
  • Acute care pricing strength supported by mix shift away from flu/lower-acuity cases and higher-acuity service lines (cardiology, orthopedics, neurology)
  • Technology-driven revenue cycle efficiency: eight deployed/scaled AI use cases yielding benefits in denials management and revenue capture

Business Development

  • Talkspace acquisition (announced March 9); Talkspace network of ~6,000 licensed clinicians across all 50 states
  • AI partner Hippocratic AI (new 2026 clinical/efficiency use cases in roadmap)

AI IconFinancial Highlights

  • Reported net income attributable to UHS per diluted share: $5.65; adjusted EPS: $5.62 for Q1 2026
  • Revenue growth: +9.6% YoY; adjusted EBITDA net of NCI: +8.4% YoY; adjusted EPS: +16.1% YoY
  • Acute care volumes impacted ~200 bps (weaker flu/respiratory activity + winter weather); behavioral weather impact ~40–50 bps on volume growth
  • Acute same-facility revenue +8.2% (+6.2% excluding health plan); acute revenue per adjusted admission +6.3% reported (+4.9% excluding ~$30m Nevada prior-period supplemental program net benefit)
  • Behavioral same-facility net revenues +7.3% driven by revenue per adjusted patient day +5.8% and patient days +1.6%; behavioral EBITDA +8.4%
  • Contract labor at 2.3% of acute revenues, 40 bps lower YoY; acute same-facility segment EBITDA +11.7%
  • Health Insurance Exchange (HIX) trends: estimated Q1 impact of ~$15m; reiterated full-year $75m pretax negative impact related to higher effective HIX decline
  • Out-of-period Medicaid supplemental payments identified: $46m combined Nevada + Ohio DPP; management said this was within expectations and excluded from underlying run-rate analysis
  • Effective EBITDA multiple for Talkspace expected: single-digit by year 3 post-closing; deal expected accretive to earnings in first 12 months post-closing

AI IconCapital Funding

  • Capital expenditures: $217m in Q1 2026
  • Share repurchases: 675,000 shares for $127m during Q1 2026
  • Buyback authorization: $1.3b remaining as of 03/31/2026; management expects continued activity through 2026 around Talkspace closing
  • Credit facilities: expanded aggregate capacity by $900m in late April for flexibility with Talkspace and M&A plus capital returns
  • Revolving credit facility: $373m borrowings outstanding; borrowing capacity expanded to $1.5b
  • Capital allocation stance: reiterated annual buyback target $800m–$900m as a minimum; Talkspace expected to modestly raise leverage from ~<2x to ~>2x

AI IconStrategy & Ops

  • 2026 AI governance focus: clinical operations efficiency/patient experience via new Hippocratic AI-enabled use cases (financial impact too early to quantify)
  • Operational de-risking approach: active revenue cycle tech/personnel/process investments to keep pace with payers and manage denials (no material increase in denials claimed)
  • Facility ramp messaging: new de novos and bed capacity expected to drive back-half earnings (Cedar Hill D.C. improvement described as back-end loaded due to weather/dynamics)
  • Behavioral outpatient scaling narrative: Thousand Branches initiative deployment slower due to state-by-state factors; not cited as the driver of Talkspace decision
  • New facility details: 156-bed de novo hospital in Florida scheduled to open in May; 178 beds (two bed towers + replacement hospital) coming online in Q2; 144-bed de novo joint venture hospital in Pennsylvania opened early Q1; 120-bed de novo hospital planned in Missouri later in 2026

AI IconMarket Outlook

  • 2026 guidance reiterated from Feb 25; reevaluate during Q2 earnings (planned for July)
  • Core growth expectation: target embedded in guidance of ~5% core level growth for remainder of year (management indicated Q1 core was not yet at 5% excluding DPP/nonrecurring items)
  • Behavioral volume framework: behavioral volume impacted by winter weather; excluding weather, still expected to be within/near the low end of the 2%–3% volume target in-quarter

AI IconRisks & Headwinds

  • HIX/premium nonpayment risk: management increased reserve in Q1 due to patients expected to lose coverage after premium failures; reserve reflects a low-double-digit effective HIX decline (~10%–12%) vs reported ~5% volume decline; could reach 25%–30% for the year
  • Unpredictable seasonal volume headwinds: acute volumes impacted ~200 bps (flu/respiratory + winter weather); behavioral volume impacted ~40–50 bps
  • Flu recovery limits: weather-related closures may be operationally recovered but flu-related lost patient days are not recaptured
  • Professional fees pressure: guidance assumed inflationary single-digit growth, possibly toward high-single digits; ongoing mitigation via competitive RFPs and reduced locums usage

Q&A: Analyst Interest

  • Acute core EBITDA bridge: Management emphasized that weather/flu, DPP comparisons, and mix changes explain quarter weakness. They said they understood difficult Q1 DPP comparisons, were not at the guidance-embedded 5% core growth level in Q1 ex-DPP, and expected ramp as the year progresses.
  • HIX bad debt/uncompensated care: Management described a conservative accounting posture after HIX volume declined ~5% in Q1 but effective coverage loss was projected higher (~10%–12% in reserves). They reiterated the annual $75m pretax estimate and warned the impact would grow through the year.
  • AI use cases and Talkspace synergy: Management clarified AI work is mostly in revenue-cycle administration (eight scaled use cases including denials management and revenue capture). For clinical operations, they plan patient-experience improvements and step-down continuity; Talkspace clinician capacity is positioned to expand virtual higher-acuity offerings.

Sentiment: MIXED

Note: This summary was synthesized by AI from the UHS Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for UHS.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (UHS)

© 2026 Stock Market Info — Universal Health Services, Inc. (UHS) Financial Profile